Data Insights

Sirexatamab by Leap Therapeutics for Colorectal Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Colorectal Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Gastric Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Gastric Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Hepatocellular Carcinoma

Data Insights

Sirexatamab by Leap Therapeutics for Endometrial Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Endometrial Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Uterine Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Uterine Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Fallopian Tube Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Fallopian Tube Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Esophageal Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Esophageal Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Sirexatamab by Leap Therapeutics for Peritoneal Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Peritoneal Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Epithelial Ovarian Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Metastatic Biliary Tract Cancer: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Metastatic Biliary Tract Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Metastatic Biliary Tract Cancer

Data Insights

Sirexatamab by Leap Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Risk adjusted net present value: What is the current valuation of Leap Therapeutics's Sirexatamab?

Sirexatamab is a monoclonal antibody commercialized by Leap Therapeutics, with a leading Phase II program in Adenocarcinoma Of The Gastroesophageal...

Net Present Value Model: Leap Therapeutics Inc's Sirexatamab